TABLE 3.
Site I1 n (%) | Site I2 n (%) | Site I3 n (%) | Site C1 n (%) | Site C2 n (%) | Total n (%) | |
---|---|---|---|---|---|---|
Therapy duplications | ||||||
Identified | 3 (4.8) | 4 (9.5) | 2 (12.5) | 16 (6.5) | 5 (2.7) | 30 (5.8) |
Resolved | 3 (100.0) | 3 (75.0) | 2 (100.0) | 12 (75.0) | 3 (60.0) | 23 (76.6) |
New duplications at follow-up | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (0.8) | 0 (0.0) | 2 (0.4) |
Drug-disease interactions | ||||||
Identified | 1 (1.6) | 1 (2.4) | 0 (0.0) | 11 (4.4) | 2 (1.4) | 15 (2.9) |
Referred | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (31.3) | 1 (50.0) | 6 (40.0) |
Resolved | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (80.0) | 0 (0.0) | 4 (66.7) |
New interaction at follow-up | 0 (0.0) | 1 (2.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.2) |
Drug-drug interactions | ||||||
Identified | 5 (7.9) | 2 (4.8) | 0 (0.0) | 29 (11.7)a | 6 (4.1) | 42 (8.1) |
Referred | 3 (60.0) | 0 (0.0) | 0 (0.0) | 10 (34.5) | 2 (33.3) | 15 (35.7) |
Resolved | 1 (33.3) | 0 (0.0) | 0 (0.0) | 4 (40.0) | 2 (100.0) | 7 (46.6) |
Safety concerns | ||||||
Identified | 7 (11.1) | 5 (11.9) | 0 (0.0) | 35 (14.1) | 8 (5.4) | 55 (10.6) |
Referred | 4 (57.1) | 3 (60.0) | 0 (0.0) | 29 (82.9) | 7 (87.5) | 43 (78.2) |
Resolved | 4 (100.0) | 0 (0.0) | 0 (0.0) | 4 (13.8) | 1 (14.3) | 9 (20.9) |
Dose-related concerns identified | ||||||
Too high | 3 (42.9) | 2 (40.0) | 0 (0.0) | 13 (44.8) | 4 (50.0)b | 22 (40.0) |
Too low | 2 (28.6) | 3 (60.0) | 0 (0.0) | 22 (62.9) | 4 (50.0) | 31 (56.4) |
Other | 2 (28.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (3.6) |
Adverse drug reactions identified | 14 (22.2) | 7 (16.7) | 3 (18.8) | 46 (18.5) | 18 (12.2) | 88 (17.0) |
Medication interventions | 237 | |||||
Interventions per patient | 0.46 |
Notes: Sites I1, I2, and I3 = independent community pharmacies; sites C1 and C2 = community health center pharmacies. Percentages may not equal 100% due to rounding.
aC1 had a higher proportion of drug-drug interactions identified than C2 (P = 0.016).
bC1 had a higher number of dose-related concerns than C2 (P = 0.011).